Business
ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa
-- Supports plans to advance TAVNEOS®(avacopan) into Phase III development for the treatment of patients with most severe form of hidradenitis suppurativa,
About this update from Chemocentryx Inc.
[{"type":"text","content":"-- Supports plans to advance TAVNEOS®(avacopan) into Phase III development for the treatment of patients with most severe form of hidradenitis suppurativa, Hurley Stage III -- SAN CARLOS, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that a poster will be presented at the Society for Investigative Dermatology (SID) 2022 Annual Meeting, to be held May 18-21, 2022 in Portland, Oregon, that highlights unique immunological profiles of the subdermal tunnels in hidradenitis suppurativa, and how these profiles are differentiated with the stage of disease severity. The findings support the Company’s plans to advance TAVNEOS® (avacopan) into Phase III development for the treatment of patients with Hurley Stage III (severe) hidradenitis suppurativa. The poster titled, Spatial Transcriptomic Analysis of HS Skin Lesions Reveals that Tunnels are Immunologically Active and Activity Correlates with Disease Severity, will be presented as part of Poster/Exhibit Hall Session 2 on Friday, May 20 between 4:30 PM– 6:30 PM PT. Hidradenitis suppurativa (HS) is a chronic, disabling, inflammatory skin disease characterized by neutrophil-rich inflammatory nodules, abscesses, and tunnels (sinus tracts). Complement dysregulation and neutrophil activation have been implicated in the pathogenesis of HS. The complement 5a (C5a) receptor (C5aR) is highly expressed on neutrophils and is a major driver of the pro-inflammatory functions. Clinical assessment of the severity of HS includes staging using the Hurley system, where Hurley Stage III disease defines severe HS and Hurley Stage II denotes a more moderate disease presentation. At the SID 2022 Annual Meeting, ChemoCentryx will present data that show a marked increase in dermal inflammation in severe Hurley Stage III HS lesions compared to moderate Hurley II lesions. Genes for proinflammatory cytokines, chemokines, neutrophil activation factors, and B cells had higher expression in the severe compared to moderate HS lesions. The spatial gradients of cytokine and chemokine gene expression support the idea that more differentiated tunnels in Hurley III disease are intensely immunologically active, potentially contributing to ongoing active severe disease, rather than merely remnant structures of prior disease. TAVNEOS, a potent and specific inhibitor of human C5aR,...